無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

CAR-T細胞療法の世界市場:市場機会・臨床パイプラインの分析

Global CAR T Cell Therapy Market Opportunity & Clinical Pipeline Insight 2024

発行 KuicK Research 商品コード 745767
出版日 ページ情報 英文 400 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.42円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
CAR-T細胞療法の世界市場:市場機会・臨床パイプラインの分析 Global CAR T Cell Therapy Market Opportunity & Clinical Pipeline Insight 2024
出版日: 2018年11月16日 ページ情報: 英文 400 Pages
概要

当レポートでは、世界のCAR-T細胞療法の市場を調査し、CAR-T技術の発展の経緯、設計基準・作用機序、有効性改善のための各種アプローチ、臨床パイプラインの動向、上市済み製品の分析、市場規模の推移と予測、競合環境と主要事業者のプロファイル、将来の展望などをまとめています。

第1章 キメラ抗原受容体 (CAR) T細胞療法:腫瘍免疫の新しい時代

  • 概要
  • CAR-T技術の発展の経緯

第2章 キメラ抗原受容体 (CAR) T細胞の設計・開発

  • CAR-T細胞の構造
  • 第1世代キメラ抗原受容体
  • 第2・3世代CAR-T細胞

第3章 キメラ抗原受容体の設計基準

  • CAR改変T細胞:ターゲティング
  • CAR改変T細胞:シグナル伝達

第4章 CAR-T細胞療法のデリバリー:パイプライン・作用機序

  • CAR-T細胞療法のプロセス
  • 作用機序

第5章 CAR-T細胞療法の有効性改善のための各種アプローチ

  • イントロダクション
  • CAR-T細胞による腫瘍間質のターゲティング
  • サイトカインネットワークのターゲティング
  • CAR-T細胞の併用戦略
  • 免疫チェックポイントのターゲティング

第6章 世界のCAR-T細胞療法:癌治療向け臨床試験

  • 急性リンパ性白血病
  • 多発性骨髄腫
  • 脳腫瘍
  • リンパ腫
  • 固形腫瘍

第7章 CAR-T細胞療法市場の分析:製品別

  • Kymriah:Novartis
  • Yescarta:Gilead

第8章 CAR-T細胞市場に影響を及ぼす近年の発展・進歩

第9章 CAR-T細胞療法の売上分析

第10章 コスト分析・市場の潜在性

  • 製造コストの分析
  • 価格分析
  • 見込み顧客基盤・収益の推計・分析

第11章 世界のCAR-T細胞療法市場:概要

  • 癌免疫療法の市場シェア:技法別
  • CAR-T細胞療法市場の規模

第12章 世界のCAR-T細胞療法:市場力学

  • 有利なパラメーター
  • 課題

第13章 世界のCAR-T細胞療法市場:将来の展望

第14章 CAR-T細胞療法の臨床パイプライン:企業・適応症・フェーズ別

  • 研究
  • 前臨床
  • 臨床
  • 第I相
  • 第I相/II
  • 第I相I

第15章 上市済みCAR-T細胞療法:臨床分析

  • Axicabtagene Ciloleucel (Yescarta)
  • Tisagenlecleucel (Kymriah)

第16章 競合環境

  • Autolus
  • Bellicum
  • Bluebird
  • Celgene
  • Cellectis
  • Celyad
  • Eureka Therapeutics
  • Fortress Biotech
  • Immune Therapeutics
  • Juno Therapeutics
  • Kite Pharma
  • Novartis
  • Sorrento therapeutics
  • TILT Biotherapeutics
  • Ziopharm
目次

" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights:

  • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action
  • Sales Analysis of CAR - T Cell Therapy
  • CAR - T Cell Therapy Market Opportunity: US$ 700 Million
  • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies
  • CAR-T Cell Therapies in Highest Phase: Preclinical
  • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah)
  • Global Market Scenario of CAR T Cell Therapy
  • Global CAR T Cell Therapy Market Future Prospects

The research in immunotherapy has unlocked the way to harness an individual's immune response to fight against the tumors and cancers. Many of the ideas have tried to make the use of natural killer cells or B cell, however, the research has not moved a past conceptual thinking. Immuno-oncology is an evolving treatment modality with the agents which being studied for their potential to provide the long term survival across a broad range of tumor types.

It is important to determine the advancement in this field and the use of new immunotherapies to achieve the best patient outcomes. The area of investigation is broad and includes the combining or sequencing the immunotherapies which target the immune pathways and sequencing an immunotherapeutic agent. CD-19 redirected chimeric antigen receptor is one of the immunotherapeutic modality which has been recently demonstrated the efficiency in re-inducing the remission in patients with multiply relapse B-acute lymphoblastic leukemia.

The global CAR-T cell therapy market boasts of a robust clinical pipeline under development with more than 200 products under various stages of development. As of 2018, only two products - Yescarta by Gilead Science and Kymriah by Novartis have made it into the market. Both the products have been approved by the FDA for the treatment of acute lymphoblastic leukemia (ALL), a rare type of blood cancer.

The global CAR-T cell therapy market is dominated by US due to its early entry into the segment followed by the European Union. However, owing to the growing prevalence of Blood cancer in Europe, the CAR-T cell market might become a burgeoning market in the region during the forecast period. The global CAR-T cell market is bound to grow leaps and bound with a staggering CAGR of 40%, crossing the US$ 700 Million mark by 2024 driven by better market penetration, affordability and accessibility,.

KuicK Research report on the ‘global CAR-T cell Therapy market' is a result of intensive study of the novel segment and its future market potential. The report has been made with key focus on the current market trends, CAR-T cell products and their superiority to traditional cancer therapy methods. The report also provides key insights into the market performance of existing CAR-T cell products, recent developments and market dynamics that might impact its future. The report concludes with effective forecast data and future projections which clearly highlights it as one of the most promising market in the modern cancer therapy segment.

Table of Contents

1. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology

  • 1.1. Overview
  • 1.2. History & Development of CAR-T Technology

2. Development of Chimeric Antigen Receptor (CAR) T-Cell Design

  • 2.1. Structure of CAR-T Cell
  • 2.2. 1st Generation Chimeric Antigen Receptor
  • 2.3. 2nd & 3nd Generation CAR-T Cell

3. Chimeric Antigen Receptor Design Standards

  • 3.1. CAR Modified T-Cells: Targeting
  • 3.2. CAR Modified T-Cell: Signaling

4. CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action

  • 4.1. Process of CAR T-Cell Therapy
  • 4.2. Mechanism of Action

5. Approaches to Improve the Efficacy of CAR-T Cell Therapy

  • 5.1. Introduction
  • 5.2. Targeting the Tumor Stroma with CAR-T Cells
  • 5.3. Targeting the Cytokine Networks
  • 5.4. Combination Strategies for CAR-T Cells
  • 5.5. Targeting the Immune Checkpoints

6. Global CAR T-Cell Therapy - Clinical Trials for Cancer Treatment

  • 6.1. Acute Lymphoblastic Leukemia
  • 6.2. Multiple Myeloma
  • 6.3. Brain Tumors
  • 6.4. Lymphoma
  • 6.5. Solid Tumors

7. CAR-T Cell Therapy Market Analysis by Product

  • 7.1. Kymriah by Novartis
  • 7.2. Yescarta by Gilead

8. Recent Advances Impacting the CAR - T Cell Market

9. Sales Analyis of CAR - T Cell Therapy

10. Cost Analysis & Market Potential of CAR - T Cell Therapy

  • 10.1. Manufacturing Cost Analysis of CAR-T Cell Therapy Products
  • 10.2. Price Analysis of CAR-T Cell Therapy
  • 10.3. Global - Estimated Potential Customer Base & Revenue Analysis

11. Global CAR T-Cell Therapy Market Overview

  • 11.1. Market Share of Cancer Immunotherapy by Technique
  • 11.2. CAR-T Cell Therapy Market Value

12. Global CAR-T Cell Therapy Market Dynamics

  • 12.1. Favorable Parameters
  • 12.2. Challenges

13. Global CAR-T Cell Therapy Market Future Outlook

14. Global CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase

  • 14.1. Research
  • 14.2. Preclinical
  • 14.3. Clinical
  • 14.4. Phase-I
  • 14.5. Phase-I/II
  • 14.6. Phase-II

15. Marketed CAR-T Cell Therapies Clinical Insight

  • 15.1. Axicabtagene Ciloleucel (Yescarta)
  • 15.2. Tisagenlecleucel (Kymriah)

16. Competitive Landscape

  • 16.1. Autolus
  • 16.2. Bellicum
  • 16.3. Bluebird
  • 16.4. Celgene
  • 16.5. Cellectis
  • 16.6. Celyad
  • 16.7. Eureka Therapeutics
  • 16.8. Fortress Biotech
  • 16.9. Immune Therapeutics
  • 16.10. Juno Therapeutics
  • 16.11. Kite Pharma
  • 16.12. Novartis
  • 16.13. Sorrento therapeutics
  • 16.14. TILT Biotherapeutics
  • 16.15. Ziopharm

List of Figures

  • Figure 1-1: Historical Development of CAR-T Cell Therapy
  • Figure 2-1: Structure of Chimeric Antigen Receptor
  • Figure 2-2: First Generation Chimeric Antigen Receptor
  • Figure 2-3: Second Generation Chimeric Antigen Receptor
  • Figure 2-4: Third Generation Chimeric Antigen Receptor
  • Figure 3-1: Targeting Mechanism of Chimeric Antigen Receptor T-Cell
  • Figure 3-2: Signalling Mechanism of Chimeric Antigen Receptor T-Cell
  • Figure 4-1: Delivery Pipeline of CAR-T Cell Therapy Process
  • Figure 4-2: CAR T Cell Therapy Mechanism of Action
  • Figure 5-1: Strategies to Improve CAR T Cell Therapy
  • Figure 6-1: CAR T Cell Therapy in Brain Tumors
  • Figure 6-2: Chimeric Antigen Receptor Therapy in Lymphoma
  • Figure 6-3: Target of Cancer Cell by Chimeric Antigen Receptor
  • Figure 7-1: Kymriah - Product Overview
  • Figure 7-2: Yescarta - Product Overview
  • Figure 9-1: US - Total Lymphoblastic Leukemia Patients & Kymriah Eligible Patients(%), 2018
  • Figure 9-2: Global - Kymriah Sales (US$ Million), 2018
  • Figure 10-1: Adoptive T-Cell Therapy Clinical Trials to Investigate the Efficacy & Safety (%), 2018
  • Figure 10-2: CAR-T cell - Estimated Manufacturing Cost (US$), 2018
  • Figure 10-3: Price Analysis - CAR-T Cell Therapy (US$/Patient), 2018
  • Figure 10-4: US - Distribution of CMS & out of Pocket Cost in CAR T Cell (US$/patient), 2018
  • Figure 10-5: Yescarta - Complete Cost Analyis for CAR T-Cell Treatment (US$), 2018
  • Figure 10-6: US - Incidence of Acute Lyphocytic Leukemia (‘000'), 2018
  • Figure 10-7: US - Estimated Patient Base for CAR T cell Therapy (Number), 2018
  • Figure 10-8: US - Current Market Revenue v/s Total Potential Revenue of CAR T cell Therapy (US$), 2018
  • Figure 10-9: Europe - Total Eligible Patients v/s Patients Receiving CART T Cell Treatment (Number), 2018
  • Figure 11-1: Cancer Immunotherapy - Market Size of CAR T Cell by Technique (%), 2018
  • Figure 12-1: Favorable Market Parameters of CAR T Cell Therapy
  • Figure 12-2: Challenges to Market Growth of CAR T Cell Therapy
  • Figure 13-1: Global - Cancer Immunotherapeutic Market Forecast (US$ Billion), 2018-2024
  • Figure 13-2: Future Potential Immuno-Oncology
  • Figure 13-3: Global - CAR T Cell Therapy Market Opportunity (US$ Million), 2018 -2024
  • Figure 14-1: Global - CAR-T Cell Therapies Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 14-2: Global - CAR-T Cell Therapies Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 14-3: Global - Discontinued CAR-T Cell Therapies Clinical Pipeline by Phase (%),2018 till 2024
  • Figure 14-4: Global - Discontinued CAR-T Cell Therapies Clinical Pipeline by Phase (Number), 2018 till 2024

List of Tables

  • Table 3-1: Antigens which are targeted by Chimeric Antigen Receptor
  • Table 16-1: Clinical Pipelines of Products
Back to Top